WuXi Buys Abgent, a US-China Antibody Maker

WuXi PharmaTech, a leading China CRO, has acquired Abgent, Inc., a provider of antibodies and custome services based in Suzhou and San Diego. The price was not disclosed. Because Abgent is a well-established antibody manufacturer, the transaction underscores the growing importance of biologics to WuXi’s business. Dr. Ge Li, Chairman and CEO of WuXi characterized the acquisition as “small but strategically important.” More details.... Stock Symbol: (NYSE: WX)